# NAME OF THE MEDICINAL PRODUCT

Glucose B. Braun 200 mg/ml Solution for infusion

## COMPOSITION

1000 ml of solution for infusion contain:

Glucose monohydrate 220.0 g (equivalent to glucose) (200.0 g)

Excipients:

Water for injection, hydrochloric acid (for pH adjustment)

## THERAPEUTIC INDICATIONS

Administration of glucose for caloric support; carbohydrate component in parenteral nutrition; treatment of hypoglycemia.

## **CONTRAINDICATIONS**

Hyperglycemia, not responding to insulin doses of up to 6 units insulin/hour, delirium tremens if such patients are already dehydrated, acute states of shock and collapse, metabolic acidosis, hyperhydration, pulmonary edema, acute cardiac failure.

## **UNDESIRABLE EFFECTS**

Undesirable effects are listed according to their frequencies as follows:

Not known: (cannot be estimated from the available data)

Metabolism and nutrition disorders

Not known: Hospital-acquired hyponatremia

Nervous system disorders

Not known: Hyponatremic encephalopathy

Hospital-acquired hyponatremia may cause irreversible brain injury and death due to the development of acute hyponatremic encephalopathy.

## **WARNINGS**

Keep out of the sight and reach of children. For single use only. Discard unused contents. Do not reconnect partially used containers. Use only if solution is clear and colourless or slightly yellowish and container and closure are undamaged.

# **NOTE**

Prescription only

Not all products are registered and approved for sale in all countries or regions. Indications of use may also vary by country and region. Please contact your country representative for product availability and information.

B. Braun Melsungen AG, 34212 Melsungen, Germany, 01/2018



# **Document Control**& Signature Page

Title: 20 % w/v Glucose Intravenous Infusion Initiator: Alina? Roman

This document is signed electronically in compliance with the B. Braun electronic signature policies and procedures by following persons:

UserName: Pfleging, Petra (pflepede)

Title: HC-RA-DE08 Manager Global Regulatory Affairs Pharmaceuticals

Date: Tuesday, 14 May 2019, 10:35 W. Europe Daylight Time

Meaning: Document signed as Author

\_\_\_\_\_

UserName: Nagel, Norbert (nagenode)

Title: HC-ME-DE08C - Senior Manager Medical Scientific Affairs HC Date: Wednesday, 15 May 2019, 12:50 W. Europe Daylight Time

Meaning: Approve Document

\_\_\_\_\_